Lung Cancer Metastatic
Conditions
Keywords
adipo-myokines, body composition, end stage lung cancer, clinical outcomes
Brief summary
The investigators conduct this prospective study and wish to elucidate the association of serial change of body composition, serum adipo-myokines and adverse effect of chemotherapy and lung cancer prognosis
Detailed description
Recently, the skeletal muscle was viewed as having biochemical function in additional to traditional biomechanical function. What's more important is that muscles could synthesize and release adipo-myokines during contraction. The adipo-myokines can affect muscle regeneration, muscle atrophy, muscle mass, autophagy, fatty acid oxidation and mitochondrial biosynthesis.Studies have also found that exercise can promote the function of macrophages and regulate both pro-inflammatory and anti-inflammatory phenotypes, helping the body to establish a stable immune balance. Since body composition can illustrate malnutrition status and cancer cachexia present, and body composition can be affected by serum adipo-myokines level. Therefore, the investigators conduct this study and wish to see the association of serial body composition and serum adipo-myokines changes with lung cancer clinical outcomes and adverse effect of any anti-cancer regimen.
Interventions
None listed
Sponsors
Chang Gung Memorial Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
1. Diagnosis of lung cancer stage III to stage IV 2. Adults over 20 years old 3. Daily performance status of 0- 2
Exclusion criteria
1\. Cardiac stents or pacemakers
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of white blood cell change among before, during and after cancer therapy | week 0 , week 4 and week 12 after cancer theraphy | assessing the change of white blood cell count among week 0, week 4 and week 12 |
| Percentage of body fat change among before, during and after cancer therapy | week 0 , week 4 and week 12 after cancer theraphy | assessing the change of percentage of body fat among week 0, week 4 and week 12 |
| Percentage of total body water change among before, during and after cancer therapy | week 0 , week 4 and week 12 after cancer theraphy | assessing the change of total body water percentage among week 0, week 4 and week 12 |
| Percentage of soft lean mass change among before, during and after cancer therapy | week 0 , week 4 and week 12 after cancer theraphy | assessing the change of soft lean mass percentage among week 0, week 4 and week 12 |
| Concentration of plasma CEA change among before, during and after cancer therapy | week 0, week 4 and week 12 after cancer theraphy | assessing the change of plasma CEA concentration among week 0, week 4 and week 12 |
| Concentration of plasma albumin change among before, during and after cancer therapy | week 0 , week 4 and week 12 after cancer theraphy | assessing the change of plasma albumin concentration among week 0, week 4 and week 12 |
| Concentration of plasma myostatin change among before, during and after cancer therapy | week 0 , week 4 and week 12 after cancer theraphy | assessing the change of plasma myostatin concentration among week 0, week 4 and week 12 |
| Concentration of plasma FSTL-1 change among before, during and after cancer therapy | week 0 , week 4 and week 12 after cancer theraphy | assessing the change of plasma FSTL-1 concentration among week 0, week 4 and week 12 |
| Concentration of plasma IL-6 change among before, during and aftercancer therapy | week 0 , week 4 and week 12 after cancer theraphy | assessing the change of plasma IL-6 concentration among week 0, week 4 and week 12 |
| Concentration of plasma irisin change among before, during and after cancer therapy | week 0 , week 4 and week 12 after cancer theraphy | assessing the change of plasma irisin concentration among week 0, week 4 and week 12 |
| Concentration of plasma adiponectin change among before, during and after cancer therapy | week 0 , week 4 and week 12 after cancer theraphy | assessing the change of plasma adiponectin concentration among week 0, week 4 and week 12 |
| Concentration of plasma MCP-1 change among before, during and after cancer therapy | week 0 , week 4 and week 12 after cancer theraphy | assessing the change of plasma MCP-1 concentration among week 0, week 4 and week 12 |
| Concentration of plasma aquaporin change among before, during and after cancer therapy | week 0 , week 4 and week 12 after cancer theraphy | assessing the change of plasma aquaporin concentration among week 0, week 4 and week 12 |
Countries
Taiwan
Contacts
Primary ContactTSENG CHIA-CHENG
Outcome results
None listed